Dr. Wasim E. Deeb, M.D.
Endocrinology & Diabetes (Endocrinology, Diabetes & Metabolism Physician)
- Medicare participating
At a glance
- Years since graduation
- 32
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 853
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Endocrinology, Diabetes & Metabolism Physician primary
FL license ME102044
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Health Medical Center - Jacksonville Jacksonville, FL
- Baptist Medical Center Beaches Jacksonville Beach, FL
- Flagler Hospital Saint Augustine, FL
- Baptist Medical Center - Nassau Fernandina Beach, FL
- Ascension St Vincent's Southside Jacksonville, FL
Medical groups
- First Choice Endocrinology LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 853
- Services billed
- 18,440
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Injection, denosumab, 1 mg | 11,460 | 116 |
| Established patient office or other outpatient visit, 30-39 minutes | 1,430 | 688 |
| Injection of drug or substance under skin or into muscle | 660 | 317 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 429 | 224 |
| Hemoglobin a1c level | 280 | 210 |
| Established patient office or other outpatient visit, 40-54 minutes | 202 | 116 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 189 | 89 |
| Blood glucose (sugar) test performed by hand-held instrument | 162 | 128 |
| New patient office or other outpatient visit, 45-59 minutes | 104 | 104 |
| New patient office or other outpatient visit, 60-74 minutes | 40 | 40 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pioglitazone Hcl Other prescribers in Jacksonville, FL | 1,295 |
| Rosuvastatin Calcium Other prescribers in Jacksonville, FL | 701 |
| Synjardy Xr (empagliflozin/metformin hcl) Other prescribers in Jacksonville, FL | 688 |
| Levothyroxine Sodium Other prescribers in Jacksonville, FL | 674 |
| Vitamin D2 (ergocalciferol (vitamin d2)) Other prescribers in Jacksonville, FL | 641 |
| Ozempic (semaglutide) Other prescribers in Jacksonville, FL | 620 |
| Liothyronine Sodium Other prescribers in Jacksonville, FL | 533 |
| Unithroid (levothyroxine sodium) Other prescribers in Jacksonville, FL | 471 |
| Jardiance (empagliflozin) Other prescribers in Jacksonville, FL | 443 |
| Atorvastatin Calcium Other prescribers in Jacksonville, FL | 338 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 37 companies reported 244 payments worth $37,978 in total to this clinician.
| Novo Nordisk Inc | $26,350 |
|---|---|
| Amgen Inc. | $5,445 |
| Cequr Corporation | $2,596 |
| Insulet Corporation | $401 |
| Abbott Laboratories | $358 |
| Madrigal Pharmaceuticals | $269 |
| Dexcom, Inc. | $247 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $199 |
| Compensation for services other than consulting (speaking, faculty) | $28,453 |
|---|---|
| Food and Beverage | $5,518 |
| Consulting Fee | $2,790 |
| Travel and Lodging | $1,209 |
| Education | $7.80 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,504 |
| Novo Nordisk Inc May 15, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $4,069 |
| Novo Nordisk Inc Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $3,023 |
| Cequr Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) CeQur Simplicity · Diabetes | $2,275 |
| Amgen Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) EVENITY · Bone Health | $2,200 |
| Amgen Inc. Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) EVENITY · Bone Health | $2,200 |
| Novo Nordisk Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Novo Nordisk Inc Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Novo Nordisk Inc Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Novo Nordisk Inc Sep 30, 2025 | Consulting Fee | $1,395 |
All 19 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novo Nordisk Inc Nov 13, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Ascendis Pharma Endocrinology Inc Nov 12, 2025 | Education Yorvipath · Endocrinology · in-kind | $7.80 |
| Novo Nordisk Inc Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $494 |
| Novo Nordisk Inc Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Novo Nordisk Inc Sep 30, 2025 | Consulting Fee | $1,395 |
| Novo Nordisk Inc Sep 29, 2025 | Consulting Fee | $1,395 |
| Amgen Inc. Sep 25, 2025 | Compensation for services other than consulting (speaking, faculty) EVENITY · Bone Health | $2,200 |
| Novo Nordisk Inc Sep 4, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $2,093 |
| Novo Nordisk Inc Aug 29, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $930 |
| Novo Nordisk Inc May 20, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $930 |
| Novo Nordisk Inc May 15, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $4,069 |
| Novo Nordisk Inc May 15, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Palm Coast, FL · in-kind | $753 |
| Novo Nordisk Inc Apr 30, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $3,023 |
| Amgen Inc. Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) EVENITY · Bone Health | $2,200 |
| Novo Nordisk Inc Mar 8, 2025 | Compensation for services other than consulting (speaking, faculty) Ozempic · Diabetes | $5,504 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $399 |
| Novo Nordisk Inc Mar 8, 2025 | Travel and Lodging Ozempic · Diabetes · travel to Orlando, FL · in-kind | $57.51 |
| Cequr Corporation Feb 28, 2025 | Compensation for services other than consulting (speaking, faculty) CeQur Simplicity · Diabetes | $2,275 |
| Amgen Inc. Feb 10, 2025 | Compensation for services other than consulting (speaking, faculty) EVENITY · Bone Health | $551 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 13 industry-funded studies in 2025, from 10 companies. The companies reported $597,413 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. · Active, not recruiting · NCT06345339 - A Phase II Randomised Double blind Placebo controlled Study to Evaluate the Efficacy Safety and Tolerability of AZD6234 Co administered with a GLP 1 Receptor Agonist in Participants with Type 2 Diabetes and Overweight…
AstraZeneca UK Limited - A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)
Novartis Pharmaceuticals Corporation - M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients…
Alnylam Pharmaceuticals Inc. - A phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure…
AstraZeneca Pharmaceuticals LP - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants
AbbVie Inc. - ISM2411001A--Prolongation of GLP-1 Adherence when using Continuous Glucose Monitoring
Abbott Laboratories - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.